3D Printing Stocks – And What Is Happening With 3D Printing Firm Organovo?
The recent slide over the last few weeks has been spawned from the company’s latest secondary offering in which they raised an additional $40 million at a $4.25 share price. This struck a nerve with investors and provided yet another opportunity to rake in the profits. While the market didn’t love this news, in my opinion, as well as that of the company, this was a move to insure that Organovo remains a market leader within the bioprinting space. With around $90 million in cash on hand and no debt, Organovo now has a balance sheet which would make any biotech company envious.
While analysts don’t expect the company to realize a profit until sometime in 2019, the magnitude of what Organovo is trying to do certainly makes their market cap of $345 million seem appealing, especially when the company recently estimated their current planned areas of research could lead to $400+ in annual revenue in the long run.
Nothing is a certainly, especially in the bioprinting industry, much less the 3D printed biotech industry, but Organovo has a significant lead on the competition and has built a strong foundation for future success with partnerships with companies like L’Oréal and Merck. Any hint at a wildly successful product, either through these partnerships or their own R&D, could lead to a $1 billion+ buyout offer in the long run even if the company is not yet profitable.